Company Overview and News
Signal Genetics, Inc. (MGEN - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. (106-0)
Post the 2016 debacle, the biotech space raised hopes with growing stability this year. However, the sector has been witnessing a correction since October. It has lost 10.4% so far in the fourth quarter of 2017 (Oct 1 to date). A major factor that resulted in this correction is the uncertainty surrounding the passing of the tax reform. (88-0)
Chicago, IL – Dec 5, 2017 - Stocks in this week’s article include: BioTime Inc. (BTX - Free Report) , Ritter Pharmaceuticals Inc. (RTTR - Free Report) , Organovo Holdings Inc. (ONVO - Free Report) , Signal Genetics Inc. (MGEN - Free Report) and Stratasys Ltd. (SSYS - Free Report) . (200-2)
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The general perception is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind investors’ inclination toward low P/E stocks. (121-0)
Dicerna Pharmaceuticals (DRNA) may be headed down the same hole that buried Genta, an infamous biotech darling-turned-disaster. (60-0)
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will follow at that time. As a reminder, today’s call is being recorded. (43-0)
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Miragen Therapeutics, Inc. (NASDAQ: MGEN) ("Miragen"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MGEN. The Company announced on October 13, 2017, new interim results from its ongoing Phase-1 clinical trial, designed to evaluate the safety, efficacy, and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). (58-0)
* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting (43-0)
August 16, 2017 - Boulder Ventures V, L.p. has filed a SC 13D/A form disclosing ownership of 82,490 shares of Miragen Therapeutics (NASDAQ:MGEN) corresponding to a(n) 0.4 ownership percentage.
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will be given at that time. As a reminder, this conference is being recorded.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton